Epidemiological, clinical & pharmacological study of antimony resistant
C.P. Thakur, S. Narayan* & A. Ranjan*
Balaji Utthan Sansthan & *Rajendra Memorial Research Institute of Medical Sciences, Patna, India
Received October 7, 2003
Background & objectives:
Sodium antimony gluconate (SAG) is reported to be losing its efficacy
in Bihar as a first line drug for treatment of visceral leishmaniasis (VL).
Concerned with the increasing incidence of antimony-resistant VL patients in Bihar, we undertook an epidemiological, clinical and pharmacological study to formulate a scientific basis for choosing a suitable first line drug for VL
_________________________________
 |
RESIST EN INDIA 2004.pdf 34K Descargar documento |
Escrito por Antonio Rondon Lugo el 22 de febrero de 2007 con
0 comentarios.
Lee más artículos sobre Articulos cientificos
